Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 34
Semaglutide and pancreatic cancer risk
A 2026 meta-analysis of randomised trials found no increased pancreatic cancer risk with semaglutide, consistent with two earlier reviews of the GLP-1 class.
Semaglutide QoL gains: real but modest
A 2026 meta-analysis finds semaglutide 2.4 mg improves physical functioning scores, but gains fall below clinically meaningful thresholds.
Semaglutide vs dulaglutide in UK practice
A UK cohort study of 6,616 adults found semaglutide lowered HbA1c by 0.22 points more than dulaglutide over one year, with 1.92 kg more weight loss.
BPC-157 in Q2 2026: what actually changed
The FDA removed BPC-157 from Category 2 in April 2026 and scheduled a PCAC review for July. The regulatory pathway shifted. The evidence picture did not.
CJC-1295 Q2 2026: what changed this quarter
CJC-1295 remains unapproved. The FDA's PCAC meets in July 2026 but CJC-1295 is not on its agenda. Two 2026 reviews confirm the clinical evidence has not moved.
Ipamorelin Q2 2026: what changed
Quarterly ipamorelin review: the HHS reclassification announcement, a still-pending FDA Category 1 move, and no new trial data.
PT-141 Q2 2026: the obesity pivot
Bremelanotide entered the obesity combination space this quarter. BMT-801 phase 2 data and next-generation MC4R compounds reshape the PT-141 picture.
What experts said about Semax this quarter
Three preclinical studies, a gerontology review and an FDA compounding meeting. What researchers published on Semax in Q2 2026.
What experts said about TB-500 in Q2 2026
On-record expert commentary on TB-500 from Q2 2026: three orthopaedic reviews, Topol's cancer-biology warning, and the upcoming FDA PCAC review.
Tesamorelin: what experts said, Q2 2026
Tesamorelin has one FDA approval and plenty of off-label hype. Here is what named experts said this quarter.
Boerhaave syndrome after semaglutide use
A 2026 case report describes the first documented esophageal perforation linked to GLP-1 agonist-induced vomiting after skipping dose titration.
What experts said about BPC-157 in Q2 2026
A digest of on-record expert commentary on BPC-157 from Q2 2026, with credentials, conflicts of interest, and the evidence gaps each expert flagged.